Can less immunosuppression save kidneys after transplant?

NCT ID NCT00213590

Completed Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving kidney transplant patients a lower dose of the drug cyclosporine could protect their kidney function over time. 208 patients who were at least one year post-transplant and on stable medications took part. The goal was to balance preventing organ rejection while reducing drug side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclosporine A (reduced dose) with mycophenolate mofetil
What this could lead to: If successful, this could help kidney transplant patients maintain better kidney function with fewer side effects from immunosuppressants.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to all patients. Lowering immunosuppression could increase the risk of organ rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY FAILURE KIDNEY TRANSPLANTATION PRIMARY PREVENTION

Contacts and locations

Locations

CHU de ROUEN

Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.